X

Gilead Sciences reports Q3 earnings. Here’s everything you need to know

Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023.

Revenues came in at $7.05 billion in the September quarter, compared to $7.04 billion in the corresponding period of 2022. For fiscal 2023, the company expects product revenues to be in the range of $26.7 billion to $26.9 billion.

Adjusted net income was $2.29 per share in the third quarter, vs. $1.90 per share in the prior-year period. The company reported an unadjusted profit of $2.18 billion or $1.75 per share for the quarter, compared to $1.79 billion or $1.43 per share in Q3 2022.

Prior Performance

Related Post